Osimertinib, a third-generation EGFR-TKI, shows a better safety profile with monotherapy and is particularly useful for EGFR-TKI-resistant NSCLC with T790M mutations [34]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.